Nebilong Tablets (Nebivolol)

• Composition :
  Each tablet contains Nebivolol 2.5mg/5 mg.
• Indications :
  It is used for the treatment of essential hypertension.
• Pharmacodynamics :
  The mechanism of action of the antihypertensive response of Nebivolol has not been definitively established. Possible factors that may be involved include: decreased heart rate, decreased myocardial contractility, diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers, suppression of renin activity and vasodilation and decreased peripheral vascular resistance.
• Dosage and administration :
  One tablet, once daily with or without food
• Contraindications :
  Nebivolol is contraindicated in heart block greater than first degree, patients with cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place).
• Precautions and warnings :
  Do not abruptly discontinue nebivolol therapy in patients with coronary artery disease. Severe exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following the abrupt discontinuation of therapy with β-blockers.In general, patients with bronchospastic diseases should not receive β-blockers. Monitor glucose levels in patients with diabetes mellitus as β-blockers may mask symptoms of hypoglycemia.
• Use in pregnancy, lactation & pediatrics :
  Teratogenic effects:Pregnancy Category C. There are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.It is not known whether this drug is excreted in human milk. Because of the potential for β-blockers to produce serious adverse reactions in nursing infants, it is not recommended during nursing.Safety and effectiveness in pediatric patients have not been established.
• Drug interactions :
  Use with caution when co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) as these drugs may increase plasma levels of nebivolol. Concomitant use with digitalis glycosides and β-blockers can increase the risk of bradycardia. Reserpine or clonidine may produce excessive reduction of sympathetic activity.
• Adverse reactions :
  Drug interactions: Use with caution when co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) as these drugs may increase plasma levels of nebivolol. Concomitant use with digitalis glycosides and β-blockers can increase the risk of bradycardia. Reserpine or clonidine may produce excessive reduction of sympathetic activity. Adverse reactions: The most common adverse events areheadache and fatigue.
• Therapy Area :
  Anti-Hypertensives